KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Co-Diagnostics (CODX) Payables (2017 - 2025)

Historic Payables for Co-Diagnostics (CODX) over the last 9 years, with Q3 2025 value amounting to $1.5 million.

  • Co-Diagnostics' Payables fell 3299.12% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year decrease of 3299.12%. This contributed to the annual value of $3.3 million for FY2024, which is 12226.8% up from last year.
  • Per Co-Diagnostics' latest filing, its Payables stood at $1.5 million for Q3 2025, which was down 3299.12% from $1.6 million recorded in Q2 2025.
  • Co-Diagnostics' Payables' 5-year high stood at $3.3 million during Q4 2024, with a 5-year trough of $427144.0 in Q2 2021.
  • Moreover, its 5-year median value for Payables was $1.5 million (2025), whereas its average is $1.5 million.
  • Over the last 5 years, Co-Diagnostics' Payables had its largest YoY gain of 40378.22% in 2021, and its largest YoY loss of 6212.29% in 2021.
  • Over the past 5 years, Co-Diagnostics' Payables (Quarter) stood at $607506.0 in 2021, then skyrocketed by 56.75% to $952296.0 in 2022, then skyrocketed by 55.64% to $1.5 million in 2023, then surged by 122.27% to $3.3 million in 2024, then plummeted by 55.73% to $1.5 million in 2025.
  • Its last three reported values are $1.5 million in Q3 2025, $1.6 million for Q2 2025, and $2.7 million during Q1 2025.